Skip to main content

Research Repository

Advanced Search

All Outputs (8)

Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia (2021)
Journal Article
Naylor-Adamson, L., Chacko, A., Booth, Z., Caserta, S., Jarvis, J., Khan, S., Hart, S. P., Rivero, F., Allsup, D. J., & Arman, M. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Frontiers in immunology, 12, Article 766272. https://doi.org/10.3389/fimmu.2021.766272

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec)... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia.

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study (2021)
Journal Article
Chatzikonstantinou, T., Kapetanakis, A., Scarfò, L., Karakatsoulis, G., Allsup, D., Cabrero, A. A., Andres, M., Antic, D., Baile, M., Baliakas, P., Bron, D., Capasso, A., Chatzileontiadou, S., Cordoba, R., Correa, J. G., Cuéllar-García, C., De Paoli, L., De Paolis, M. R., Del Poeta, G., Demosthenous, C., …Ghia, P. (in press). COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01450-8

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-d... Read More about COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2021)
Journal Article
Lin, W. Y., Fordham, S. E., Hungate, E., Sunter, N. J., Elstob, C., Xu, Y., Park, C., Quante, A., Strauch, K., Gieger, C., Skol, A., Rahman, T., Sucheston-Campbell, L., Wang, J., Hahn, T., Clay-Gilmour, A. I., Jones, G. L., Marr, H. J., Jackson, G. H., Menne, T., …Allan, J. M. (2021). Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature communications, 12(1), Article 6233. https://doi.org/10.1038/s41467-021-26551-x

Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating a total of 4018 AML cases and 104... Read More about Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies (2021)
Journal Article
Pepper, A. G., Zucchetto, A., Norris, K., Tissino, E., Polesel, J., Soe, Z., Allsup, D., Hockaday, A., Ow, P. L., Hillmen, P., Rawstron, A., Catovsky, D., Bulian, P., Bomben, R., Baird, D. M., Fegan, C. D., Gattei, V., & Pepper, C. (2021). Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01322-1

COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study (2021)
Journal Article
Allsup, D., Howard, D., Emmerson, J., Hockaday, A., Rawstron, A., Oughton, J. B., Bloor, A., Phillips, D., Nathwani, A., Paneesha, S., Turner, D., Munir, T., & Hillmen, P. (in press). COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British journal of haematology, https://doi.org/10.1111/bjh.17526

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia (2021)
Journal Article
Molica, S., Allsup, D., Gianfelici, V., Levato, L., Aiello, V., Bailey, J., & Polliack, A. (in press). Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, https://doi.org/10.1080/13543784.2021.1924669

Introduction: Venetoclax has emerged as a breakthrough treatment which has revolutionized the therapeutic paradigm of chronic lymphocytic leukemia (CLL). This is primarily attributed to the efficacy of venetoclax as a time-limited, chemo-free, therap... Read More about Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia (2021)
Journal Article
Lin, W. Y., Fordham, S. E., Sunter, N., Elstob, C., Rahman, T., Willmore, E., Shepherd, C., Strathdee, G., Mainou-Fowler, T., Piddock, R., Mearns, H., Barrow, T., Houlston, R. S., Marr, H., Wallis, J., Summerfield, G., Marshall, S., Pettitt, A., Pepper, C., Fegan, C., …Allan, J. M. (2021). Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. Nature communications, 12(1), Article 665. https://doi.org/10.1038/s41467-020-20822-9

© 2021, The Author(s). Prognostication in patients with chronic lymphocytic leukemia (CLL) is challenging due to heterogeneity in clinical course. We hypothesize that constitutional genetic variation affects disease progression and could aid prognost... Read More about Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.